Becton, Dickinson and Company (NYSE:BDX), doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.
BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety. Its products support a range of clinical procedures and help healthcare organizations manage the administration of medicines and other therapies.
The company’s Life Sciences segment provides diagnostic systems, specimen-collection products, laboratory instruments and reagents, as well as research tools such as flow cytometry systems. Its Interventional segment supplies medical devices used in areas including surgery, peripheral intervention, urology and oncology. BD sells its products internationally through direct sales organizations, distributors and other commercial partners.
BD has expanded its operations over more than a century through internal development and acquisitions, building a broad portfolio of technologies used across the healthcare system. The company is a separate public entity from embecta, which was formed in 2022 through the separation of BD’s former diabetes care business.
